AIQ Solutions technology is featured in the Journal of Nuclear Medicine as a highlight of the 2022 Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference. https://jnm.snm
“Documentation of complex changes using automated response assessment shows promise for monitoring both the heterogeneity of tumor response and evolving tumor burden during radionuclide therapies, with important implications for more individualized management. This will enable us to track each individual lesion over time rather than make a summary statement that the patient as a whole is responding, which fails to address the entire biology of the underlying disease and response.”
Heiko Schöder, MD, MBA
Memorial Sloan Kettering Cancer Center and
Weill Cornell Medical College, New York, NY